BR112018007422A2 - anticorpos anti-age e métodos de uso dos mesmos - Google Patents
anticorpos anti-age e métodos de uso dos mesmosInfo
- Publication number
- BR112018007422A2 BR112018007422A2 BR112018007422A BR112018007422A BR112018007422A2 BR 112018007422 A2 BR112018007422 A2 BR 112018007422A2 BR 112018007422 A BR112018007422 A BR 112018007422A BR 112018007422 A BR112018007422 A BR 112018007422A BR 112018007422 A2 BR112018007422 A2 BR 112018007422A2
- Authority
- BR
- Brazil
- Prior art keywords
- treat
- sequence identity
- onset
- prevent
- delay
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- RRUYWEMUWIRRNB-LURJTMIESA-N (2s)-6-amino-2-[carboxy(methyl)amino]hexanoic acid Chemical compound OC(=O)N(C)[C@H](C(O)=O)CCCCN RRUYWEMUWIRRNB-LURJTMIESA-N 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000002177 Cataract Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010023509 Kyphosis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000003679 aging effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000008439 repair process Effects 0.000 abstract 1
- 208000001076 sarcopenia Diseases 0.000 abstract 1
- 230000017423 tissue regeneration Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562241007P | 2015-10-13 | 2015-10-13 | |
| US14/974,561 US10358502B2 (en) | 2014-12-18 | 2015-12-18 | Product and method for treating sarcopenia |
| PCT/US2016/034880 WO2017065837A1 (en) | 2015-10-13 | 2016-05-27 | Anti-age antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018007422A2 true BR112018007422A2 (pt) | 2018-10-30 |
Family
ID=58518256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018007422A BR112018007422A2 (pt) | 2015-10-13 | 2016-05-27 | anticorpos anti-age e métodos de uso dos mesmos |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3362483A1 (enExample) |
| JP (1) | JP2018535953A (enExample) |
| KR (1) | KR20180056689A (enExample) |
| CN (1) | CN108431044A (enExample) |
| AU (1) | AU2016336959A1 (enExample) |
| BR (1) | BR112018007422A2 (enExample) |
| CA (1) | CA3000815C (enExample) |
| IL (1) | IL258397A (enExample) |
| MA (1) | MA42979A (enExample) |
| MX (1) | MX2018004545A (enExample) |
| RU (1) | RU2766209C2 (enExample) |
| WO (1) | WO2017065837A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2616728T3 (es) | 2008-05-23 | 2017-06-14 | Siwa Corporation | Procedimientos y composiciones para facilitar la regeneración |
| WO2012047629A2 (en) | 2010-09-27 | 2012-04-12 | Siwa Corporation | Selective removal of age-modified cells for treatment of ather0sclerosis |
| US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
| IL251210B2 (en) | 2014-09-19 | 2023-12-01 | Siwa Corp | Anti-aging antibodies for the treatment of inflammation and autoimmune disorders |
| US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
| US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
| US10889634B2 (en) | 2015-10-13 | 2021-01-12 | Siwa Corporation | Anti-age antibodies and methods of use thereof |
| CN109071675A (zh) * | 2016-02-19 | 2018-12-21 | Siwa有限公司 | 使用高级糖化终产物(age)的抗体治疗癌症、杀死转移性癌细胞和预防癌症转移的方法和组合物 |
| CA3057829A1 (en) | 2016-04-15 | 2017-10-19 | Siwa Corporation | Anti-age antibodies for treating neurodegenerative disorders |
| EP3475306A1 (en) | 2016-06-23 | 2019-05-01 | Siwa Corporation | Vaccines for use in treating various diseases and disorders |
| US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
| US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
| US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
| US10858449B1 (en) | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
| US10919957B2 (en) | 2017-04-13 | 2021-02-16 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
| KR20240006702A (ko) * | 2017-05-04 | 2024-01-15 | 시와 코퍼레이션 | 진단용 최종 당화 산물 항체 |
| JP6994876B2 (ja) * | 2017-09-05 | 2022-01-14 | 株式会社エッグ | 計測器 |
| US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
| WO2019183282A1 (en) * | 2018-03-21 | 2019-09-26 | Mayo Foundation For Medical Education And Research | Senolytic agents for the treatment of tauopathies |
| WO2020023532A1 (en) * | 2018-07-23 | 2020-01-30 | Siwa Corporation | Methods and compositions for treating chronic effects of radiation and chemical exposure |
| US20210253739A1 (en) * | 2018-08-23 | 2021-08-19 | Siwa Corporation | Anticarboxymethyl lysine antibodies and ultrasound for removing age-modified cells |
| AU2021264007A1 (en) * | 2020-05-01 | 2022-12-08 | Siwa Corporation | Methods of treating infections |
| CN117642431B (zh) * | 2021-07-13 | 2025-07-15 | 迈威(美国)生物治疗有限公司 | 抗c1s抗体和其用途 |
| CN114716551B (zh) * | 2021-11-12 | 2023-01-24 | 深圳市人民医院 | 靶向rage的纳米抗体及其应用 |
| WO2023177390A1 (en) * | 2022-03-14 | 2023-09-21 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody for treating pancreatic cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
| US4917951A (en) | 1987-07-28 | 1990-04-17 | Micro-Pak, Inc. | Lipid vesicles formed of surfactants and steroids |
| US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
| US5624804A (en) * | 1991-12-20 | 1997-04-29 | The Rockefeller University | Immunochemical detection of In vivo advanced glycosylation end products |
| US6387373B1 (en) | 1993-01-15 | 2002-05-14 | Novavax, Inc. | Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants |
| US6380165B1 (en) | 1997-09-19 | 2002-04-30 | The Picower Institute For Medical Research | Immunological advanced glycation endproduct crosslink |
| GEP20104998B (en) * | 1999-06-25 | 2010-06-10 | Genentech Inc | Humanized antibody which binds erbb2 and blocks activation by ligand receptor of erbb2 (variants) and use of the composition comprising these antibodies methods for treating cancer |
| JP4012722B2 (ja) * | 2001-11-22 | 2007-11-21 | 株式会社トランスジェニック | カルボキシメチル化ペプチドに対する抗体 |
| EP1988918A4 (en) | 2006-02-22 | 2010-04-28 | Novavax Inc | ADJUVANZ AND VACCINE COMPOSITIONS |
| ES2616728T3 (es) | 2008-05-23 | 2017-06-14 | Siwa Corporation | Procedimientos y composiciones para facilitar la regeneración |
-
2016
- 2016-05-27 EP EP16731696.7A patent/EP3362483A1/en not_active Withdrawn
- 2016-05-27 CA CA3000815A patent/CA3000815C/en active Active
- 2016-05-27 WO PCT/US2016/034880 patent/WO2017065837A1/en not_active Ceased
- 2016-05-27 BR BR112018007422A patent/BR112018007422A2/pt not_active Application Discontinuation
- 2016-05-27 AU AU2016336959A patent/AU2016336959A1/en not_active Abandoned
- 2016-05-27 CN CN201680059997.5A patent/CN108431044A/zh active Pending
- 2016-05-27 JP JP2018519727A patent/JP2018535953A/ja active Pending
- 2016-05-27 MA MA042979A patent/MA42979A/fr unknown
- 2016-05-27 RU RU2018110885A patent/RU2766209C2/ru active
- 2016-05-27 MX MX2018004545A patent/MX2018004545A/es unknown
- 2016-05-27 KR KR1020187010762A patent/KR20180056689A/ko not_active Abandoned
-
2018
- 2018-03-27 IL IL258397A patent/IL258397A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018110885A (ru) | 2019-11-19 |
| WO2017065837A1 (en) | 2017-04-20 |
| CA3000815A1 (en) | 2017-04-20 |
| MX2018004545A (es) | 2018-08-01 |
| AU2016336959A1 (en) | 2018-04-12 |
| CA3000815C (en) | 2022-11-01 |
| RU2766209C2 (ru) | 2022-02-09 |
| EP3362483A1 (en) | 2018-08-22 |
| JP2018535953A (ja) | 2018-12-06 |
| KR20180056689A (ko) | 2018-05-29 |
| IL258397A (en) | 2018-05-31 |
| MA42979A (fr) | 2021-05-26 |
| RU2018110885A3 (enExample) | 2020-01-30 |
| CN108431044A (zh) | 2018-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018007422A2 (pt) | anticorpos anti-age e métodos de uso dos mesmos | |
| CL2017003132A1 (es) | Moléculas de unión a lag-3 y métodos de uso de las mismas | |
| CY1125102T1 (el) | Αντιγονοδεσμευτικες πρωτεϊνες που ενεργοποιουν τον υποδοχεα λεπτινης | |
| BR112018068189A2 (pt) | proteínas de ligação induzíveis e métodos de uso | |
| PE20150023A1 (es) | Proteinas de union a antigeno st2 | |
| EA201890278A1 (ru) | Антитела к pd-l1 | |
| BR112016030686A2 (pt) | anticorpos anti tau humanizados | |
| EA201890453A1 (ru) | Анти-angptl8 антитела и их применение | |
| BR112017016068A2 (pt) | composições para modulação de expressão de c9orf72 | |
| MX391802B (es) | Anticuerpos anti-age para el tratamiento de inflamación y trastornos autoinmunes | |
| EA201890790A1 (ru) | Связывающие pd-1 белки и способы их применения | |
| EA201591467A1 (ru) | Анти-lag-3 связывающие белки | |
| MX386491B (es) | Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn. | |
| PE20161442A1 (es) | Proteinas quimericas tipo fosfatasa alcalina | |
| PE20211272A1 (es) | POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO | |
| CO2020000369A2 (es) | Polipéptidos que se unen al componente del complemento c5 o albumina sérica y proteínas de fusión de los mismos | |
| PE20201171A1 (es) | Anticuerpos de cadena pesada que se unen a cd22 | |
| EA201900561A1 (ru) | Конъюгаты циклодекстрин-белок-лекарственное средство | |
| BR112017008525A2 (pt) | proteína de fusão isolada, e, métodos para tratamento ou alívio de um sintoma de uma doença ou distúrbio, para tratamento ou alívio de uma inflamação ou um sintoma de uma doença ou distúrbio inflamatório e para redução do risco de infecção em um indivíduo. | |
| EA201890320A1 (ru) | Молекулы антител, которые связывают cd79 | |
| WO2015198243A3 (en) | Compositions and methods for long acting proteins | |
| EA201890198A1 (ru) | Новые белки, специфичные в отношении lag-3 | |
| MX387560B (es) | Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina. | |
| BR112017006598A2 (pt) | anticorpo de repetições antidipeptídeo derivado de ser humano (dprs) | |
| EA202091350A1 (ru) | Связывающие молекулы, специфично связывающиеся с тау-белком |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |